Clicky

Patrys Limited  (PAB)

Description: Patrys Limited is engaged in the commercialization of its technologies to develop natural human antibody-based therapeutic products for the treatment of cancer. The Company is engaged in conducting research and development activities in the biopharmaceutical sector. The Company's products include PAT-SM6, PAT-LM1 and PAT-SC1. PAT-SM6 is a natural human antibody that binds to multiple types of cancer, including solid tumors, such as melanoma, breast, colon and pancreatic, as well as blood-based cancers, such as multiple myeloma. PAT-SM6 has completed its Phase I clinical trials for melanoma and Phase I/IIa clinical trials for multiple myeloma. PAT-LM1 is a natural human antibody that can be used for treatment of multiple types of cancer, with potency against colon, lung, breast, ovary and pancreatic cancers. PAT-LM1 is in pre-clinical stage of its study. It offers 3E10 Deoxymab, a lupus autoantibody. It is toxic to cancer cell that has deficiencies in deoxyribonucleic acid repair.


Keywords: Medicine Pharmaceutical Cancer Biopharmaceutical Clinical Medicine Solid Tumors Tumor Treatment Of Cancer Monoclonal Antibodies Clinical Trial Melanoma Therapeutic Products Multiple Myeloma Pancreatic Cancer Targeted Therapy Ducting Lupus Biopharmaceutical Sector

Home Page: www.patrys.com

PAB Technical Analysis

Putnam Asset Allocation Funds
,

Phone: 61 3 9670 3273


Officers

Name Title
Dr. James A. Campbell B.Sc., MBA, Ph.D. MD, CEO & Exec. Director
Ms. Valentina Dubljevic BSc, GAICD, MBB VP of Scientific & Clinical Devel.
Dr. Deanne Greenwood B.Sc., GAICD, MBA, Ph.D. VP of Bus. Devel. & Intellectual Property
Dr. Rebecca Tunstall VP of Corp. Devel.
Mr. Stefan Ross Company Sec.

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.4427
Price-to-Sales TTM: 18.5117
IPO Date: 2007-07-20
Fiscal Year End: June
Full Time Employees: 0
Back to stocks